Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

CTMX CytomX Therapeutics Inc

1,89

-0,09 (-4,55%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:09:10

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more CytomX Therapeutics Charts.

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more CytomX Therapeutics Charts.

News CytomX Therapeutics Inc

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Montag 13 Mai 2024 (1 Stunde vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 8 Mai 2024 (5 Tage vor) • Edgar (US Regulatory)

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
Mittwoch 8 Mai 2024 (5 Tage vor) • GlobeNewswire Inc.

Form 8-K - Current report
Mittwoch 8 Mai 2024 (5 Tage vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 8 Mai 2024 (5 Tage vor) • Edgar (US Regulatory)

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Dienstag 7 Mai 2024 (6 Tage vor) • GlobeNewswire Inc.

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
Mittwoch 1 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Montag 8 April 2024 (1 Monat vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Mittwoch 3 April 2024 (1 Monat vor) • GlobeNewswire Inc.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Donnerstag 21 März 2024 (2 Monate vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Montag 18 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Montag 11 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere CytomX Therapeutics Inc News-Artikel

Financial Select Sector

Deutsche Telekom (QX)

JP Morgan Chase

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen